Immunomedics, Inc. (NASDAQ:IMMU) Director David M. Goldenberg sold 40,000 shares of the stock in a transaction on Monday, March 5th. The shares were sold at an average price of $17.24, for a total transaction of $689,600.00. Following the completion of the transaction, the director now directly owns 1,774,285 shares in the company, valued at $30,588,673.40. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Shares of Immunomedics, Inc. (NASDAQ:IMMU) traded down $0.01 during trading on Monday, reaching $17.29. 1,775,357 shares of the company’s stock traded hands, compared to its average volume of 2,020,000. Immunomedics, Inc. has a 52 week low of $5.00 and a 52 week high of $18.93. The company has a debt-to-equity ratio of 1.20, a current ratio of 1.26 and a quick ratio of 1.26. The stock has a market cap of $2,630.00, a P/E ratio of -9.30 and a beta of 1.48.
Immunomedics (NASDAQ:IMMU) last issued its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.09). The business had revenue of $0.60 million for the quarter, compared to the consensus estimate of $0.90 million. sell-side analysts anticipate that Immunomedics, Inc. will post -0.96 earnings per share for the current year.
IMMU has been the topic of a number of recent analyst reports. Jefferies Group increased their target price on shares of Immunomedics from $22.00 to $27.00 and gave the company a “buy” rating in a research report on Wednesday, January 24th. BidaskClub raised shares of Immunomedics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 25th. Zacks Investment Research downgraded shares of Immunomedics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 15th. ValuEngine downgraded shares of Immunomedics from a “hold” rating to a “sell” rating in a research report on Monday, December 4th. Finally, TheStreet raised shares of Immunomedics from a “d” rating to a “c-” rating in a research report on Friday, February 9th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. Immunomedics presently has an average rating of “Buy” and a consensus price target of $19.00.
Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.